IBOV 185,724.89 ▲ 0.28% IPSA 11,315.26 ▼ 1.14% IPC MEX 65,473.16 ▲ 0.91% MERVAL 3,134,612 ▲ 0.91% COLCAP 2,510.51 ▲ 0.85% BVL PERÚ 59,719.97 ▲ 0.61% USD/BRL5.10▲ 0.24% USD/MXN16.97▼ 0.02% USD/CLP932.95▼ 0.49% USD/COP3,135▼ 1.08% USD/PEN3.36▼ 0.20% USD/ARS1,508▼ 0.18% USD/UYU40.23▲ 1.13% USD/PYG5,924▲ 2.31% USD/BOB12.30▲ 4.75% USD/DOP58.65▲ 0.17% USD/CRC447.49▲ 1.34% USD/GTQ7.63▲ 2.30% USD/HNL26.84▲ 1.66% USD/NIO36.62▲ 0.71% USD/VES802.80▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.65▲ 0.05% EUR/BRL5.93▼ 0.56% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 185,724.89 ▲ 0.28% IPSA 11,315.26 ▼ 1.14% IPC MEX 65,473.16 ▲ 0.91% MERVAL 3,134,612 ▲ 0.91% COLCAP 2,510.51 ▲ 0.85% BVL PERÚ 59,719.97 ▲ 0.61% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Thursday, September 3, 2026

Covid-19 Brazil

Covid-19 Reinfection, the Great Pandemic Puzzle

By · August 27, 2020 · 4 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – The emergence of the first cases in which an individual was again infected with the coronavirus after overcoming the disease did not come as a surprise to scientists.

On Monday, researchers from the University of Hong Kong announced that genetic tests confirmed that a patient in the region, who had been infected with a strain of the virus in April, later became infected with another strain in August after traveling to Spain.

The Netherlands and Belgium have also announced one case each, although the results have not yet been published in scientific journals, as with the Hong Kong case. Still lacking data and not knowing whether these reinfections are exceptional or frequent, these are some of the conclusions that can be drawn from these cases.

The good news is that both in the Hong Kong and Belgian patients the second infection was much lighter than the first.
The good news is that both in the Hong Kong and Belgian patients the second infection was much lighter than the first. (Photo: internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Is this bad news?

Not necessarily. Other respiratory infections, such as coryzae produced by other coronaviruses, can be repeated several times, and that SARS-CoV-2 would behave this way was already expected.

For now, these are exceptional cases after millions of infections all over the world, but even if there is a reduction in immunity over time, the good news is that both in the Hong Kong and Belgian patients the second infection was much lighter than the first.

In the case of the Asian patient, it was completely asymptomatic. Among the bad news would be “that the time between two infections was expected to be longer” than the three or four months in the cases studied, as the Belgian virologist Marc Van Ranst pointed out.

Is it likely for reinfections to be frequent?

“It seems that it is not a very common fact until now. If it were, the numbers of infected people would be much higher, particularly among those who have been in contact with infected patients, such as healthcare professionals, where it was found that they did have the disease again,” notes María Montoya, head of the Viral Immunology group at the Margarita Salas Biological Research Center, linked to the CSIC (Spanish scientific research agency).

However, “if the reinfection is due to the fact that the immunity produced in the first infection decreased, we will now begin to see more reinfections,” she adds.

What would a common reinfection imply for the development of vaccines?

Federico Martinón-Torres, head of the Paediatrics Department at the Santiago de Compostela Clinical University Hospital (Spain) and vaccine expert, warns that it is first necessary “to wait and see if more cases occur or if it is something exceptional.”

If the defenses of people who have experienced the disease decline over time, it would imply that the vaccine “would have a limited duration and revaccination would be required,” as is the case with many of the vaccines currently used.

But the fact that immunity decreases over time and fails to prevent a new reinfection does not necessarily mean that we are left unprotected. If Hong Kong and Belgium were the norm, vaccines might not make the coronavirus disappear, but they would dramatically reduce its impact, as many other vaccines do.

“One important benefit of vaccines is the protection against disease transmission to others,” notes Martinón-Torres. “This is something that happens with the pneumococcal conjugate vaccine, which produces collective protection, preventing the subject from transmitting the disease to others. In the case of the coronavirus, this would not be possible, at least in the long term.”

However, one of the most important aspects of the vaccines we already use is the protection against serious forms of diseases. “The flu vaccine does not prevent the disease, but protects against its most severe forms,” he explains. The rotavirus vaccine, which produces dangerous forms of gastroenteritis in children, does not block the disease but makes it milder. The immune system’s response to these isolated cases suggests that vaccines against the coronavirus would not make the disease disappear, but would make it milder.

Does it render herd immunity impossible?

The emergence of reinfected people would make it difficult to reach a lasting herd immunity, both from the protection produced by overcoming the disease as well as from vaccines. However, the possibility of third-party contamination by someone infected for the second time is not yet known.

In a number of studies with the coronavirus that causes catarrh, it was found that, after the first infection, the time a patient spends producing the virus and its amount decreases. Moreover, although the virus would continue to spread among people, with no herd immunity occurring, the probability that Covid-19 will be increasingly milder would produce a similar effect from a social perspective.

Source: El País

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map
All News Brazil art news Brazil Best English News Brazil Best News Brazil Brazil Brazil economy Brazil football Brazil Museum Fire Brazil national football team Brazil News Brazil Pension Reform Brazil Real Brazil Visa Brazilian Newspaper Business News Brazil Covid-19 Latin America culture news Brazil English Culture News Brazil English Info Brazil English Info Rio de Janeiro English News Argentina English News Belo Horizonte English News Bolivia English News Brasilia English News Brazil English News Chile English News Colombia English News Cuba English News Curitiba English News Ecuador English News El Salvador English News Falklands English News Florianopolis English News Guetamala English News Latin America English News Mexico English News Panama English News Paraguay English News Peru English News Rio de Janeiro English News Sao Paulo English News Uruguay English News Venezuela English Newspaper Brazil English Newspaper Rio de Janeiro Falkland Islands General News Brazil Info Brazil Info Rio de Janeiro Invest in Brazil Mining News Brazil Natioal Museum of Brazil News Argentina News Bolivia News Brasilia news Brazil News Chile News Colombia News Cuba News Ecuador News El Salvador News Falklands News Florianopolis News Guatemala News Latin America News Mexico News Panama News Paraguay News Peru News Rio de Janeiro News Uruguay News Venezuela Oil News Brazil President of Brazil Rio de Janeiro São Paulo News Science News Brazil travel Brazil Travel News Brazil Universities Brazil

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.